Anneke Van Der Walt

Projects

Projects per year 2015 2018 2019 2021 2027

• 15 Finished
• 17 Active

Projects per year

Search results

• Active

  MSBase Fellowship Award

  Sajedi, S. A., Van Der Walt, A. & Zhu, C.

  3/03/23 → 3/03/24

  Project: Research

• A Phase III randomised, placebo-controlled, double-blind, multi-centre, clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertension

  Van Der Walt, A.

  17/02/23 → 17/02/25

  Project: Research

• VALUE-Ig : eVidence synthesis to inform the optimAL UsE of Immunoglobulin

  Petrie, D., McQuilten, Z., Harris, A., Wood, E., Irving, A., Van Der Walt, A., Reddel, S. W., Fanning, L., Spencer, A., Hawkes, E. & Crispin, P.

  1/04/22 → 31/03/25

  Project: Research

• Active monitoring of cognitive function to detect preclinical changes and define longitudinal cognitive trajectories in people with multiple sclerosis

  Merlo, D. & Van Der Walt, A.

  Multiple Sclerosis Research Australia (trading as National Multiple Sclerosis Research Foundation Limited)

  1/01/22 → 31/12/24

  Project: Research

• Determining the risk of cervical precancer and cancer in women with multiple sclerosis: a national data linkage study.

  Van Der Walt, A., Jokubaitis, V., Butzkueven, H., Taylor, B. V. M., Lechner-Scott, J. & Brotherton, J. M. L.

  Multiple Sclerosis Research Australia (trading as National Multiple Sclerosis Research Foundation Limited)

  1/01/22 → 31/12/24

  Project: Research

• VISIONARY-MS LTE: A Multi-Centre, Open-Label Long-Term Extension Study Assessing the Safety, Efficacy, Tolerability, and Pharmacokinetics of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis (RMS) under Protocol number CNMAu8.201LTE

  Van Der Walt, A.

  29/07/21 → 31/12/26

  Project: Research

• A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient-reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy.

  Van Der Walt, A. & Macdonnell, R.

  16/03/21 → 31/12/26

  Project: Research

• Multi-dimensional monitoring of cognition and cerebellar function to prospectively define disease progression in multiple sclerosis

  Van Der Walt, A.

  National Health and Medical Research Council (NHMRC) (Australia)

  1/01/21 → 31/12/25

  Project: Research

• Active self-monitoring to prospectively detect treatment failure and define subclinical progression trajectories in multiple sclerosis: The ACTIVE-MS Program.

  Van Der Walt, A., Butzkueven, H., Jokubaitis, V., Kolbe, S., Vogel, A. P., Stankovich, J., Butler, E., Macdonell, R. A. L. & Darby, D.

  Trish Multiple Sclerosis Research Foundation

  1/01/20 → 31/12/23

  Project: Research

• Monash-Roche Meaningful Data at Scale Collaboration for MS

  Van Der Walt, A. & Butzkueven, H.

  Hoffmann-La Roche (Switzerland)

  6/12/19 → 31/12/27

  Project: Research

• Collaboration on Roche Managed Primary Data Collection NIS and RWD Analytics Activities

  Butzkueven, H. & Van Der Walt, A.

  Hoffmann-La Roche (Switzerland)

  6/12/19 → 1/12/26

  Project: Research

• A prospective, multicenter, observational, post-authorization safety study to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (Post Authorization Safety Study (PASS) Protocol).

  Van Der Walt, A.

  31/07/19 → 31/12/24

  Project: Research

• Active Participatory Health Monitoring in people with Multiple Sclerosis to improve treatment outcomes (Active-MS)

  Butzkueven, H., Van Der Walt, A., Darby, D., Stankovich, J., Jokubaitis, V., Skibina, O., Marriott, M., Butler, E. & Gresle, M.

  Department of Health and Aged Care (Australia)

  1/07/19 → 30/06/24

  Project: Research

• A Randomized, Controlled, Open-Label, Rater-Blinded, Phase 3b Study of the Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Subjects With Relapsing-Remitting Multiple Sclerosis Switching from Treatment with 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment Followed by an Open-Label Crossover Extension Study Comprising Subcutaneous and Intravenous Natalizumab Administration

  Van Der Walt, A.

  16/04/19 → 31/12/24

  Project: Research

• Next generation biomarkers for multiple sclerosis

  Van Der Walt, A., Kolbe, S., Butzkueven, H., Kalincik, T. & Kilpatrick, T. J.

  Biogen Australia Pty Ltd

  1/01/19 → 15/12/23

  Project: Research

• Long-term, prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started on fingolimod once daily or treated with another disease-modifying therapy.

  Van Der Walt, A. & Germaine, J.

  30/11/18 → 31/01/24

  Project: Research

• VISIONARY-MS: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study for the Treatment of Visual Pathway Deficits in Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of CNM-Au8 For Remyelination In Stable Relapsing-Remitting Multiple Sclerosis (RRMS).

  Van Der Walt, A.

  19/10/18 → 31/12/25

  Project: Research